Pipeline: Delivered on our commitment to a more focused R&D strategy by advancing a streamlined portfolio of 5+ clinical and preclinical programs in oncology and rare disease, while deprioritizing 3 ...

Recursion Pharmaceuticals is an AI-enabled drug discovery company, differentiated by its scale and focus on understanding biology. The company has a broad pipeline across various therapeutic areas and ...

Community driven content discussing all aspects of software development from DevOps to design patterns. The factorial of 5 is 120. The factorial of 10 is 3,628,800. Programmers can take one of two ...

Recursion unveils post-combination technology-enabled portfolio with more than 10 clinical and preclinical programs, 10 advanced discovery programs, and more than 10 partnered programs Platform will ...

(RTTNews) - Recursion Pharmaceuticals, Inc. (RXRX), a clinical-stage TechBio company, on Monday, announced that it is deprioritizing three of its clinical programs and one preclinical program ...

– Company Eligible to Receive Up to $25 Million, Including an Upfront Equity Payment of $7.5 Million – – Extends Rallybio Cash Runway to Mid-2027 – The REV102 program originated from a joint venture ...

Success for just one of Recursion's phase 2 programs could enable the stock to double within five years. However, the odds of success for phase 2 candidates aren't good. Risk-averse investors should ...